Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04778410 · ClinicalTrials.gov registry record · Phase 2
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04778410 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 54 participants.
The verdict
NCT04778410, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04778410
The ClinicalTrials.gov registry entry for NCT04778410 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT04778410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04778410 about?
NCT04778410 is a clinical study titled "Study of Magrolimab Combinations in Participants With Myeloid Malignancies". The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
What is the current status of trial NCT04778410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-06-28. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT04778410?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Etoposide (DRUG), Mitoxantrone (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04778410?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.